The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Novodiax sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Novodiax Inc, United States Revenue

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Novodiax is a developer of tissue-based diagnostics and immunoassays. It provides wide range of products such as intraoprative IHC kits, ihcDirect kits, primary antibodies, polyHRP detection systems for IHC and ELISA, tools, and others. It offers technologies such as direct IHC, intraoperative IHC, and supersensitive polymer detection platform, among others. Novodiax utilizes its supersensitive polymer detection platform to develop enzymatic signal detection systems, including polyHRp and poly-AP. The company also provides contract services for the design and development of customized supersensitive detection polymers for researchers ad biotech companies. It works in partnership with pharma and biotechnology companies to integrate therapeutic antibody development at various stages. Novodiax is headquartered in Hayward, California, the US.

The key metrics of Novodiax related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:

As Novodiax is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Novodiax.

For a detailed understanding of the performance of Novodiax, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s revenue report leverages GlobalData’s SKU tracker, which contains real-world, purchasing data from the US healthcare institutions.